On April 28, Inkon Life Technology Co.Ltd(300143) released the first quarter report of 2022. The announcement shows that the company achieved an operating revenue of 268 million yuan, an increase of 11% over the same period last year; The net profit attributable to the parent company was 24.11 million yuan, an increase of 31% over the same period of the previous year. The net profit attributable to the shareholders of the listed company after deducting non recurring profits and losses was 25.31 million yuan, an increase of 360% over the same period of the previous year. In 2021, the Inkon Life Technology Co.Ltd(300143) operating revenue increased by 1 billion yuan for the first time, reaching 1.090 billion yuan, a year-on-year increase of 6%.
Since the transformation in 2019, Inkon Life Technology Co.Ltd(300143) has continuously deepened its strategy around the main line of tumor treatment ecology. Starting from tumor treatment and continuously extending to the field of front-end diagnosis and back-end rehabilitation, it has built a “tumor pre diagnosis / treatment / health” experience network to provide tumor patients with one-stop and full scene medical service experience. The revenue increased rapidly in the first quarter, and the ecological brand of tumor medical technology entered the fast lane of development.
promote the construction of university courses and accelerate the development of digital medical services
At present, Inkon Life Technology Co.Ltd(300143) has actively arranged regional medical centers in the five major economic circles of the country and continuously linked high-quality tumor diagnosis and treatment resources. It has three tumor characteristic hospitals: Sichuan Friendship Hospital, Suzhou Guangci tumor hospital and Chongqing Huajian Youfang hospital. It also hosts Yuncheng No. 1 hospital, Changchun Yingkang hospital and Shanghai Yongci rehabilitation hospital.
Through the capacity-building of university departments, the development of hospitals within the Inkon Life Technology Co.Ltd(300143) system has been accelerated. Through the use of online ecology and digital infrastructure, the professional abilities of oncology University Department, rehabilitation University Department and Heart University Department are empowered to each hospital, so as to strengthen the professional capacity construction of its hospitals, so as to break the regional restrictions of medical resources, realize the cross regional circulation of advantageous disciplines and high-quality medical resources within the system, and promote the rapid growth of business volume.
Digital medical treatment is Inkon Life Technology Co.Ltd(300143) another major feature. In the regional medical center, Inkon Life Technology Co.Ltd(300143) widely carries out digital medical services that break the boundaries of time and space, builds an experience cloud platform, and builds a Wuxi Online Offline Communication Information Technology Co.Ltd(300959) integrated digital medical scene ecology for its medical institutions. Since Sichuan Friendship Hospital obtained the qualification of Internet hospital in March 2021, there have been more than 4 million online medical services and more than 130000 new users. At the same time, the internal human efficiency has been improved by 50% and the offline waiting time of users has been greatly reduced. At the same time, the hospital carried out remote online consultation services through advanced 5g technology, linked more than 1000 experts to the north, realized zero distance interaction with experts, and obtained more accurate diagnosis and treatment solutions. In the first quarter of 2022, the revenue increased by 11% year-on-year.
continue to increase R & D investment and lengthen the product line
In the field of cancer prevention and treatment, Chinese enterprises have been actively carrying out technological innovation and exploration Inkon Life Technology Co.Ltd(300143) ‘s Internet of things tumor treatment technology ecological brand Maxi has made continuous scientific and technological innovation, and the self-developed gamma knife radiotherapy equipment has broken through the technological monopoly.
In addition to radiotherapy equipment, Inkon Life Technology Co.Ltd(300143) also continued to lengthen the product line and reshape the R & D system during the reporting period. In the short term, by docking mature tumor diagnosis products, we can quickly supplement the product line, expand tumor rehabilitation products and lengthen the tumor industry chain. In the medium term, the large radiotherapy equipment dominated by gamma knife will be upgraded and iterated, the function of linear accelerator will be upgraded, and the new version will accelerate R & D and innovation. In the long run, plan the whole gene code map of human body and make a forward-looking layout of new technologies that have a great impact in the fields of tumor treatment, diagnosis and prevention.
Inkon Life Technology Co.Ltd(300143) built a 1 + 5 R & D system, that is, a shared platform, including four modules: product pre research, product registration, science and technology policy and technology management. The five R & D platforms include gamma knife, linear accelerator, small proton knife, experience cloud and advanced R & D platform. In 2021, Inkon Life Technology Co.Ltd(300143) independent R & D investment was 28.86 million yuan, a year-on-year increase of 62%.
It is understood that at present, there is still a large gap between the utilization rate of radiotherapy for cancer patients in China and the global level. The radiotherapy market has great development potential, coupled with the emerging rehabilitation needs, there are great opportunities in China’s tumor medical service market. The Inkon Life Technology Co.Ltd(300143) future, whose business covers tumor medical equipment and services, is expected to build a full course and full cycle disease treatment and health management system from the tumor scene, rehabilitation nursing scene and health management scene through the science and technology ecological strategy of tumor pre diagnosis / treatment / health scene, and realize rapid development through the expansion of service chain and industrial chain.
